Novonesis Acquires MicroBioGen to Bolster Yeast Capabilities…

Event summary

Novonesis completed the acquisition of MicroBioGen on October 1, 2026, after obtaining all regulatory approvals.
The acquisition builds on Novonesis' 2013 investment and existing 23% ownership stake in MicroBioGen.
MicroBioGen brings advanced yeast-breeding expertise, particularly in bioethanol, with broader industrial applications.
Novonesis aims to integrate MicroBioGen's capabilities to develop new biosolutions across multiple industries.

The big picture

Novonesis' acquisition of MicroBioGen underscores the growing importance of yeast-breeding expertise in industrial biotechnology. The deal reflects a broader trend of consolidation in the biosolutions sector, where companies are investing heavily in R&D to develop sustainable and efficient industrial processes. The strategic move positions Novonesis to capitalize on the increasing demand for bio-based solutions across multiple industries.

What we're watching

Integration Challenges: How Novonesis will integrate MicroBioGen's expertise into its existing R&D framework and maintain continuity for current partners.
Market Expansion: The pace at which Novonesis can leverage MicroBioGen's yeast capabilities to expand into new industries beyond bioethanol.
Strategic Alignment: Whether the acquisition aligns with Novonesis' 2030 strategy and delivers measurable growth in biosolutions.